Evidence map›Paper›PMID 34572980›Full record

ArticleAntioxidants (Basel, Switzerland)2021

Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells.

Antonio J León-González, Prudencio Sáez-Martínez, Juan M Jiménez-Vacas, Vicente Herrero-Aguayo, Antonio J Montero-Hidalgo, Enrique Gómez-Gómez, Andrés Madrona, Justo P Castaño, José L Espartero, Manuel D Gahete and 1 more

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Antonio J León-GonzálezMaimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.ORCID 0000-0003-2668-8205
Prudencio Sáez-MartínezMaimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Juan M Jiménez-VacasMaimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Vicente Herrero-AguayoMaimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Antonio J Montero-HidalgoMaimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Enrique Gómez-GómezMaimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.ORCID 0000-0002-8753-3306
Andrés MadronaDepartment of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain.
Justo P CastañoMaimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.ORCID 0000-0002-3145-7287
José L EsparteroDepartment of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain.ORCID 0000-0001-9926-7757
Manuel D GaheteMaimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.ORCID 0000-0002-4578-2179
Raúl M LuqueMaimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.ORCID 0000-0002-7585-1913
Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition · ESUniversidad de Sevilla · ESInstituto Maimónides de Investigación Biomédica de Córdoba · ES

Funding

Instituto de Salud Carlos III CD16/00092Instituto de Salud Carlos III CIBERobnInstituto de Salud Carlos III PI20/01301Junta de Andalucía BIO-0139Junta de Andalucía PI-0152-2019Junta de Andalucía RH-0084-2020Ministerio de Economía, Industria y Competitividad, Gobierno de España FPU16/06190Ministerio de Economía, Industria y Competitividad, Gobierno de España FPU17/00263Ministerio de Economía, Industria y Competitividad, Gobierno de España FPU18/02485Ministerio de Economía, Industria y Competitividad, Gobierno de España PID2019-105564RB-I00Universidad de Córdoba FEDER Andalucía: 27416
6 · The paper itself

Abstract

A high adherence to a Mediterranean diet has been related to numerous beneficial effects in human health, including a lower incidence and mortality of prostate cancer (PCa). Olive oil is an important source of phenolic bioactive compounds, mainly hydroxytyrosol (HT), of this diet. Because of the growing interest of this compound and its derivatives as a cancer chemopreventive agent, we aimed to compare the in vitro effect of HT isolated from olive mill wastewaters and five semisynthetic alkyl ether, ester, and nitro-derivatives against prostate cancer (PCa) cell lines. The effect in cell proliferation was determined in RWPE-1, LNCaP, 22Rv1, and PC-3 cells by resazurin assay, the effect in cell migration by wound healing assay, and tumorsphere and colony formation were evaluated. The changes in key signaling pathways involved in carcinogenesis were assessed by using a phosphorylation pathway profiling array and by Western blotting. Antiproliferative effects of HT and two lipophilic derivatives [hydroxytyrosyl acetate (HT-Ac)/ethyl hydroxytyrosyl ether (HT-Et)] were significantly higher in cancerous PC-3 and 22Rv1 cells than in non-malignant RWPE-1 cells. HT/HT-Ac/HT-Et significantly reduced migration capacity in RWPE-1 and PC-3 and prostatosphere size and colony formation in 22Rv1, whereas only HT-Ac and HT-Et reduced these functional parameters in PC-3. The cytotoxic effect in 22Rv1 cells was correlated with modifications in the phosphorylation pattern of key proteins, including ERK1/2 and AKT. Consistently, HT-Ac and HT-Et decreased p-AKT levels in PC-3. In sum, our results suggest that HT and its lipophilic derivatives could be considered as potential therapeutic tools in PCa.

Indexed as

anticancerextra virgin olive oilhydroxytyrosolprostate cancersemisynthetic derivatives

Identifiers

PMID34572980
PMCPMC8464900
OpenAlexW3195283483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.